Celularity Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Florham Park, NJ. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $27 million and a loss of $92 million (its filed statements).
Product businessPharmaceutical PreparationsFlorham Park, NJfilings since 20188 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.3 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.5 out of ten, present 3.6 out of ten, future 2.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.4 out of ten. 25 warning events since 2018; the latest 2026-08-14. 4th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.7 out of ten. +13.2% a year over 6 filed years; profitable in 1 of 6. 57th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.9 out of ten. CrossAssetData estimate 3.9/10, confidence 35 of 100 (one part). 39th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 3.0 out of ten. Leverage 135%: owes 135¢ per asset dollar. 30th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.9 out of ten. bottom 49% of 314 in its family; net margin -345.4%. 49th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 2.9 out of ten. bottom 29% of 315 in its family for leadership; chief executive since 2021. 29th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 3.0 out of ten. bottom 30% of 272 in its family for room to expand. 30th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 2.5 out of ten. bottom 25% of 307 in its family for growth drivers. 25th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 2.3 out of ten. bottom 23% of 234 in its family for expectations against reality. 23rd percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-04-30 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-09-29 for the period ended 2026-03-31 (on EDGAR). Newest results release: Form 8-K filed 2025-05-09 (on EDGAR). Newest filing: Form 8-K, 2026-09-29. Filings on record since 2018. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Degenerative Disease 65%, Biobanking 21%, Cell Therapy 14%. As tagged in its annual report (Form 10-K, filed 2026-04-30).
Who runs it
Hariri, Robert J (Chief Executive Officer); Haines, John R (Senior Exec Vice President); Dossantos, Joseph (Interim CFO); Brigido, Stephen (Pres., Functional Regeneration); Barach, Philip Alan (director); Diamandis, Peter (director); Levien, Vincent (director); Ling, Geoffrey M.d. (director); Parks, Diane L. (director); Lim, Kok Thay (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.